<DOC>
	<DOCNO>NCT02364492</DOCNO>
	<brief_summary>The purpose study evaluate maximum tolerate dose ( MTD ) obtain follow 2 administration MAG-Tn3 + AS15 cancer vaccine administer dose 30 µg , 100 µg 300 µg IM every three week .</brief_summary>
	<brief_title>A Phase I Study Therapeutic Vaccine Candidate Patients With Localized Breast Cancer High-Risk Relapse</brief_title>
	<detailed_description>This study three dose level open-label , non-randomized , dose-escalation study Phase I safety vaccine candidate MAG-Tn3 + AS15 administer patient HER2 negative , high-risk localize breast cancer remission . A maximum 30 patient include study : - 3 6 patient 1st dose level ( 30 µg ) - 6 12 patient 2nd dose level ( 100 µg ) - 6 12 patient 3rd dose level ( 300 µg ) The clinical study phase I compose vaccination period 4 month ( 16 week ) follow-up period 36 month ( 3 year ) . Each patient receive one three escalate dos MAG-Tn3 combination fix dose AS15 adjuvant . The subject receive 6 vaccine injection , administer intramuscular injection 3-weeks interval injection . Each patient follow 36 month last injection . The follow-up period compose short-term follow-up period 6 month long-term follow-up period 30 month . A total 20 visit require patient . Clinical data blood sample collect analysis patient . Clinical study data record patient source documentation enter electronic CRFs ( eCRFs ) use proprietary Electronic Data Capture ( EDC ) Clinical Data Base Software System . The eCRF data enter site personnel train EDC data entry . A monitor visit site regularly check completeness patient record , accuracy entry e-CRFs , adherence protocol Good Clinical Practice , progress enrollment , ensure study drug store , dispense , account accord specification . Institut Pasteur designate CRO conduct data management . Data enter EDC house central database . Changes track provide audit trail . Interactive data check carry applicable data entry process . Additional data check program identify error SAS datasets . Applicable query base SAS datasets add EDC resolution data management personnel . At conclusion study , data enter source document verify , outstanding query remain , Investigator site require electronically sign patient 's casebook confirm data patient complete accurate consistent patient 's source document . The data lock prevent editing . Concomitant medication enter database cod use WHO Drug Reference List , employ Anatomical Therapeutic Chemical classification system . Medical history/current medical condition adverse event terminology cod use Medical dictionary regulatory activities.The new version dictionary data base lock use .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . All patient must diagnosis epithelial breast carcinoma , accord TNM classification : Any T With Positive ( N+ ) Negative ( N ) LymphNode depend patient profile And Non metastatic ( M0 ) 2 . HER2/neunegative ( Immunohistochemical expression `` 01+ '' , and/or FISH/CISH `` non amplify '' accord ASCO 2012 criterion ) 3 . First line treatment population HighRisk Relapse define : least 4 positive lymph node ( LN ) primary surgery , least one positive lymph node &gt; pN1mi completion 68 cycle anthracyclins/taxanesbased neoadjuvant chemotherapy Or , negative hormone receptor : ER PR , ( &lt; 10 % ) , i.e `` Triple Negative breast cancer '' With least one positive lymph node &gt; pN1mi negative lymph node pathological complete remission achieve ( persistence invasive carcinoma ) completion 68 cycle anthracyclins/taxanesbased neoadjuvant chemotherapy 4 . Patients must complete local regional treatment include adequate surgery radiation therapy , least 6 cycle chemotherapy ( neoadjuvant and/or adjuvant ) accord institutional national standard . 5 . The time interval end first line standard treatment ( completion surgery , chemotherapy radiation therapy ) least 3 month within maximum 18 month inclusion study . 1 . Any breast cancer recurrence metastasis . 2 . Patients HER2/neu positive breast carcinoma ( IHC score 2+ 3+ and/or FISH/CISHamplified ) . 3 . Patients uncontrolled bleed disorder include coagulation disorder thrombocytopenia prothrombotic disorder . 4 . Patients personal history autoimmune disease ( include limit multiple sclerosis , lupus , rheumatoid polyarthritis , inflammatory bowel disease , Graves ' disease Hashimoto 's disease ) . 5 . Patients history previous anaphylaxis severe allergic reaction vaccine know unknown allergen . 6 . Patients receive commercial vaccine within one month first dose study vaccine plan receive vaccine till 3 week 6th vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>[ C04.588.180 ]</keyword>
</DOC>